The “Cerco al Alzheimer” event, held on September 14, 2023, at the European University of Alcobendas, brought together some of the leading specialists in the field of dementia to discuss the current state of research, new therapies, and diagnostic methods in an open format.
One of the key topics discussed mainly during the first two panels of the day was the importance of assessing the risk of both rapid disease progression and the occurrence of serious side effects with new treatments in newly diagnosed patients who may receive these monoclonal antibodies.
These risks can be assessed through the plasma analysis of specific biomarkers in the patient, specifically Apolipoprotein E4 (APOE4), which is already available in Spain.
Video Summary video panel 1
Video Summary video panel 2
Full Session
